Abbott Laboratories (Pakistan) Limited: Financial Results for the Quarter Ended March 31, 2026
Summary
Abbott Laboratories (Pakistan) Limited reported a strong financial performance for Q1 2026 with net profit increasing to Rs 1.94 billion and net sales reaching Rs 17.70 billion.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Net Sales | PKR 17.70 billion | PKR 17.35 billion | +2.0% |
| Net Profit | PKR 1.94 billion | PKR 1.60 billion | +21.3% |
| Gross Profit | PKR 6.70 billion | PKR 5.84 billion | +14.7% |
| Earnings Per Share | PKR 19.82 | PKR 16.34 | +21.3% |
| Cash and Bank Balances | PKR 12.47 billion | PKR 13.34 billion | -6.5% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Net sales increased to Rs 17.70 billion, up from Rs 17.35 billion in the same period last year, indicating a growth in revenue.
- Net profit for the period rose to Rs 1.94 billion, showing a significant increase from Rs 1.60 billion in the prior year.
- Gross profit improved to Rs 6.70 billion from Rs 5.84 billion, reflecting better cost management and sales performance.
Abbott Laboratories (Pakistan) Limited (ABOT) on Nafa
Last price Rs 1,000.00 · Pharmaceuticals · You can own ABOT shares from your phone.
More ABOT announcements
- NoticeTransmission of Quarterly Reports for the Period Ended September 30, 2026
- Financial resultAbbott Laboratories (Pakistan) Limited reported a strong financial performance for the nine months ended September 30, 2026Filed as: Financial Results for the Quarter Ended September 30, 2026
- NoticeBoard Meeting
- NoticeTransmission of Quarterly Financial Statements for the Period Ended June 30, 2026
- NoticeBoard Meeting
- NoticeRe-Appointment of Chairman
Source: Abbott Laboratories (Pakistan) Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.